【Healthkoreanews】The Pacific pharma's 'KETOTOP(Ketoprofen)' is registered on the list of the Over The Counter(OTC) in U.S. Food and Drug Administration(FDA), according to the Pacific pharma's announcement on 17 Dec.
KETOTOP is indicated as an analgesic and anti-inflammatory agent for osteoarthritis.
An offical of the company said, "We recevied the approval letter for sale in U.S. from FDA and now we are mapping out various strategies for U.S. market".
The Health Insurance Review and Assessment Service (HIRA) excluded KETOTOP from the list of drugs which are covered by the national health insurance last April.
As a result, the sales of KETOTOP have been rapidly decreasing since that time. <헬스코리아뉴스>